Keyphrases
Mouse Model
100%
Effective Treatment
100%
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Fibroblast Growth Factor 1 (FGF1)
100%
Steatosis
100%
Steatohepatitis
100%
Recombinant
50%
Peroxisome Proliferator-activated Receptor
37%
Thiazolidinediones
37%
Adverse Effects
25%
Lipid Catabolism
25%
Type 2 Diabetes Mellitus (T2DM)
12%
Leptin
12%
Obesity
12%
Gene-deficient Mice
12%
Pharmacological Treatment
12%
Anti-inflammatory Properties
12%
Insulin Resistance
12%
Anti-inflammatory Effect
12%
Fibrosis
12%
Hepatic Steatosis
12%
Nuclear Receptor
12%
Liver Function
12%
Serious Adverse Effects
12%
Hepatic Inflammation
12%
Glucose-lowering Drugs
12%
Visceral Adipose Tissue
12%
Glucose-insulin System
12%
Hepatic Lipid
12%
Choline-deficient
12%
Insulin Sensitizers
12%
Hepatic Damage
12%
Patients with Obesity
12%
Therapeutic Targeting
12%
Adipose Remodeling
12%
Chronic Liver Disorders
12%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse Model
100%
Nonalcoholic Fatty Liver
100%
Steatosis
100%
Fibroblast Growth Factor 1
100%
Adverse Event
37%
Thiazolidinedione
37%
Peroxisome Proliferator Activated Receptor Gamma
25%
Ob/Ob Mouse
25%
Disease
12%
Epileptic Absence
12%
Mouse
12%
Non Insulin Dependent Diabetes Mellitus
12%
Inflammation
12%
Insulin Resistance
12%
Liver Disease
12%
Anti-Inflammatory Drug
12%
Antiinflammatory Activity
12%
Fatty Liver
12%
Fibrosis
12%
Leptin
12%
Choline
12%
Peroxisome Proliferator Activated Receptor Gamma Agonist
12%
Cell Nucleus Receptor
12%
Recombinant Fibroblast Growth Factor
12%